Walter K Kraft

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. ncbi Pharmacologic management of the opioid neonatal abstinence syndrome
    Walter K Kraft
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1170 Main Building, 132 South 10th Street, Philadelphia, PA 19107, USA
    Pediatr Clin North Am 59:1147-65. 2012
  2. ncbi A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study
    Roslyn Varki
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South 10th Street, 1170 Main Building, Philadelphia, PA 19107, USA
    BMC Clin Pharmacol 9:2. 2009
  3. ncbi Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial
    Walter K Kraft
    Department of Pharmacology and Experimental Therapeutics, Jefferson Medical College, Philadelphia, PA 19107, USA
    Pediatrics 122:e601-7. 2008
  4. ncbi Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome
    Walter K Kraft
    Department of Pharmacology and Experimental Therapeutics Pediatrics, Jefferson Medical College, Philadelphia, PA, USA
    Addiction 106:574-80. 2011
  5. ncbi Clinical pharmacology: a paradigm for individualized medicine
    Scott A Waldman
    Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA
    Biomark Med 3:679-84. 2009
  6. ncbi Prevalence of obstructive lung disease in HIV population: a cross sectional study
    Amyn Hirani
    Division of Pulmonary and Critical Care Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    Respir Med 105:1655-61. 2011
  7. ncbi Obstructive sleep apnea syndrome and postoperative complications: clinical use of the STOP-BANG questionnaire
    Tajender S Vasu
    Division of Pulmonary and Critical Care Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
    Arch Otolaryngol Head Neck Surg 136:1020-4. 2010
  8. ncbi Pharmacokinetic evaluation of fosaprepitant dimeglumine
    Francheska Colon-Gonzalez
    Thomas Jefferson University, Department of Pharmacology and Experimental Therapeutics, 1170 Main Building, 132 S 10th St, Philadelphia, PA 19107, USA
    Expert Opin Drug Metab Toxicol 6:1277-86. 2010

Detail Information

Publications8

  1. ncbi Pharmacologic management of the opioid neonatal abstinence syndrome
    Walter K Kraft
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1170 Main Building, 132 South 10th Street, Philadelphia, PA 19107, USA
    Pediatr Clin North Am 59:1147-65. 2012
    ..Emerging trends in the treatment of infants with NAS include the use of sublingual buprenorphine, transition to outpatient therapy, and pharmacogenetic risk stratification...
  2. ncbi A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study
    Roslyn Varki
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South 10th Street, 1170 Main Building, Philadelphia, PA 19107, USA
    BMC Clin Pharmacol 9:2. 2009
    ..AVI-014 is an egg white-derived, recombinant, human granulocyte colony-stimulating factor (G-CSF). This healthy volunteer study is the first human investigation of AVI-014...
  3. ncbi Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial
    Walter K Kraft
    Department of Pharmacology and Experimental Therapeutics, Jefferson Medical College, Philadelphia, PA 19107, USA
    Pediatrics 122:e601-7. 2008
    ..Secondary goals were to evaluate efficacy relative to standard therapy and to characterize buprenorphine pharmacokinetics when sublingually administered...
  4. ncbi Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome
    Walter K Kraft
    Department of Pharmacology and Experimental Therapeutics Pediatrics, Jefferson Medical College, Philadelphia, PA, USA
    Addiction 106:574-80. 2011
    ..Current treatments are associated with prolonged hospitalization. We sought to optimize the dose of sublingual buprenorphine in the treatment of NAS...
  5. ncbi Clinical pharmacology: a paradigm for individualized medicine
    Scott A Waldman
    Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA
    Biomark Med 3:679-84. 2009
    ....
  6. ncbi Prevalence of obstructive lung disease in HIV population: a cross sectional study
    Amyn Hirani
    Division of Pulmonary and Critical Care Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    Respir Med 105:1655-61. 2011
    ..Observational studies have suggested an association between HIV infection and emphysema...
  7. ncbi Obstructive sleep apnea syndrome and postoperative complications: clinical use of the STOP-BANG questionnaire
    Tajender S Vasu
    Division of Pulmonary and Critical Care Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
    Arch Otolaryngol Head Neck Surg 136:1020-4. 2010
    ....
  8. ncbi Pharmacokinetic evaluation of fosaprepitant dimeglumine
    Francheska Colon-Gonzalez
    Thomas Jefferson University, Department of Pharmacology and Experimental Therapeutics, 1170 Main Building, 132 S 10th St, Philadelphia, PA 19107, USA
    Expert Opin Drug Metab Toxicol 6:1277-86. 2010
    ..Due to formulation issues, aprepitant is only available for oral administration. Fosaprepitant, a prodrug of aprepitant, was introduced to the market in 2008 as an intravenous bioequivalent to aprepitant...